Experimental antitumour activity of S 16020-2 in a panel of human tumours

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1881-1887

  Kraus Berthier, L ^a   Guilbaud, N ^a   Jan, M ^a   Saint Dizier, D ^a   Rouillon, M H ^a   Burbridge, M F ^a   Pierre, A ^a   Atassi, G ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Human tumours; Pgp; S 16020 2; Topoisomerase II; Xenografts

Indexed keywords

2 [9 HYDROXY 5,6 DIMETHYL 1 [N (DIMETHYLAMINO)ETHYL]CARBAMOYL] 6H PYRIDO[4,3 B]CARBAZOLE; CISPLATIN; DOXORUBICIN; GYRASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COLONIC NEOPLASMS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ELLIPTICINES; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031414927     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00232-3     Document Type: Article

References (20)

1. Zunino F, Capranico G. DNA topoisomerase II as the primary target of antitumor anthracyclines. Anti Cancer Drug Design 1990, 5, 307-317.
2. Fosse P, Rene B, Charra M, Paoletti C, Saucier JM. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine dériva-tives: structure-activity relationship. Mol Pharmacol 1992, 42, 590-595.
3. Rowe T, Kupfer G, Ross W. Inhibition of epidophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 1985, 34, 2483-2487.
4. Ross WE. DNA topoisomerases as target for cancer therapy. Biochem Pharmacol 1985, 34, 4191-4195.
5. Jasztold-Howorko R, Landras C, Pierre A, et al. Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5, 6-dimethyl)-6H-pyrido[4, 3-e]carbazole-1 -AT-(dialkylamino)alkyl] carboxamides, a new promising series of antitumor olivacine derivatives. J Med Chew. 1994, 37, 2445-2452.
6. Léonce S, Ferez V, Casabianca-Pignede MR et al. In vitro cytotoxicity of S 16020-2, a new olivacine derivative. Invest New Drugs 1996, 14, 169-180.
7. Le Mee S, Markovits J, Pierre A, et al In vitro studies of S 16020-2, a new antitumour pyridocarbazole derivative. Fifth Conference on DNA topoisomerases in therapy, New York, 1994.
8. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, et al. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother Pharmacol 1996, 38, 513-521.
9. Kraus-Berthier L, Guilbaud N, Léonce S, et al. Antitumor effect of S 16020-2 against experimental lung carcinoma. Proc Am Assoc Cancer Res 1995, 36, 386.
10. Auclair C, Pierre A, Voisin E, et al. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HC1. Cancer Res 1987, 47, 6254-6261.
11. Boyd MR, Kenneth DP. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Development Res 1995, 34, 91-109.
12. Dykes DJ, Abbott BJ, Mayo JG, et al. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. In Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Basel, Karger, 1992, 42, 1-22.
13. Kolaric K. Chemotherapy of mammary cancer with anthracyclines and alkylators. In Nicolini M, ed. Platinum and other Metal Coordination Compounds in Cancer Chemotherapy. Boston, MA, M. Nijhoff, 1988, 436-449.
14. Greco FA, Richardson RL, Snell JD, Stroup SL, Oldham RK. Small cell lung cancer-complete remission and improved survival. Am J Med 1979, 66, 625-630.
15. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Onco/1984, 11, 251-263.
16. Arvelo F, Poupon MF, Le Chevalier T. Establishment and characterization of five human small-cell lung cancers cell lines from early tumor xenografts. Anticancer Res 1994, 14, 1893-1902.
17. Fodstad 0. Preclinical anticancer drug evaluation in human tumor xenografts. In Fiebig HH, Berger DP, eds. Immunodeficient Mice in Oncology. Basel, Karger, 1992, 42, 352-361.
18. Fiebig HH, Berger DP. Preclinical Phase II trials. In Boven E, Winograd B, eds. The Nude Mouse in Oncology Research. Boca Raton, FL, CRC Press, 1991, 317-326.
19. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer xenografts. Science 1989, 2 1046-1048.
20. Poupon MF, Arvelo F, Goguel AF, et al. Response of small-cell lung cancer xenograft to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 1993, 85, 2023-2029.